The vaccine in the vial is slowly and carefully shaken to dilute the dendritic cells which adhere to the vial surface. The quantity of the vaccine is about 2 ml in small animals and 5 ml in horses.
According to the stage, anatomical site and personal situation of the patient the recommended vaccination instructions vary:

• Case 1: Solid Tumor – non or only partially resectable
  
  If the tumor is solid and non or only partially resectable, because
  • of the size or location of the tumor or metastases
  • the personal clinical situation of the patient (age, multi-disease)
  • it is no general anaesthesia possible
  • the wish of the owner for a non-surgical approach

  the vaccination can be administered directly into the tumor tissue, if the veterinarian can reach the tumor site with an injection needle (for skin or subcutaneous tumors). Depending on the tumor size, 1 to 2 ml of the vaccine should be given directly in the the tumor (site). The second fraction of the vaccine should be given in a clipped or hairless area intradermally (see case 2).
  
  Special uses of the DC-vaccine in non-resectable cases are:

  • If the animal shows a nonresectable tumor in the thoracal cavity the vaccine is administered as shown in case 2 and 3.
  • If the pet has a nonresectable tumor of the abdominal cavity the vaccine is administered solely intradermally (case 2).
• Case 2: Vaccination intradermally
  
  The intradermal application is the normal form of treatment with dendritic cell vaccines. The most convenient locations for the vaccination are used:
  • In dogs in the inguinal area (inner thighs, because it is normally an hairless area, you don’t have to clip)
  • in cats you can clip an area in the paraspinal area, so you don’t have to turn the animal
  • in horses normally the neck area.

  You can also use (any) other skin areas after clipping and desinfection, if this is of more comfort for patient and therapist. You can also use the already clipped postsurgical site. After the vaccination the dendritic cells migrate to the nearest lymph vessel and the following lymph node to induce a specific t-cell-stimulation.

• Case 3: Intraveneous Injection
  
  The intraveneous vaccination is used in the follwing indications:
  • Lung tumors or lung metastases
  • Non resectable tumor in the thoracal cavity
  • Only small experience: Brain tumors or brain
  • Part of the vaccine is injected intraveneously. The other half of the vaccine is used intradermally (case 2). Petbiocell produces two different vials for this indication.
• Case 4: Postsurgical use of vaccine
  
  If the tumor tumor was surgically removed the vaccination is administered in the following two-tier way:
  • In the operation site or around the skin suture intracutaneously or deeper into the tissue.
  • At another location as shown in case 2